| CircCPA4 induces ASCT2 expression to promote tumor property of non-small cell lung cancer cells in a miR-145-5p-dependent manner. | CircCPA4 induces ASCT2 expression to promote tumor property of non-small cell lung cancer cells in a miR-145-5p-dependent manner.
Zhang Z, Liu W, Huang T, Li J, Hu H, Xu X, Fan Z., Free PMC Article | 04/11/2024 |
| circCPA4 induces malignant behaviors of prostate cancer via miR-491-5p/SHOC2 feedback loop. | circCPA4 induces malignant behaviors of prostate cancer via miR-491-5p/SHOC2 feedback loop.
Xu W, Zhong Z, Gu L, Xiao Y, Chen B, Hu W., Free PMC Article | 02/5/2024 |
| Carboxypeptidase A4 negatively correlates with p53 expression and regulates the stemness of breast cancer cells. | Carboxypeptidase A4 negatively correlates with p53 expression and regulates the stemness of breast cancer cells.
Wang Y, Xie Y, Niu Y, Song P, Liu Y, Burnett J, Yang Z, Sun D, Ran Y, Li Y, Sun L., Free PMC Article | 11/6/2021 |
| Carboxypeptidase A4 promotes cardiomyocyte hypertrophy through activating PI3K-AKT-mTOR signaling. | Carboxypeptidase A4 promotes cardiomyocyte hypertrophy through activating PI3K-AKT-mTOR signaling.
Gao W, Guo N, Zhao S, Chen Z, Zhang W, Yan F, Liao H, Chi K., Free PMC Article | 03/27/2021 |
| Findings suggest that the angiotensin II (Ang II) generation from hAng-(1-12) is primarily mediated by chymase rather than carboxypeptidase A (CPA). | Mast cell peptidases (carboxypeptidase A and chymase)-mediated hydrolysis of human angiotensin-(1-12) substrate.
Ahmad S, Wright KN, Sun X, Groban L, Ferrario CM., Free PMC Article | 06/6/2020 |
| CPA4 promotes CRC cell growth via activating the STAT3 and ERK pathways and may be a prognostic factor or therapeutic target for CRC | Carboxypeptidase A4 promotes cell growth via activating STAT3 and ERK signaling pathways and predicts a poor prognosis in colorectal cancer.
Pan H, Pan J, Ji L, Song S, Lv H, Yang Z, Guo Y. | 02/1/2020 |
| we revealed that CPA4 downregulation may induce apoptosis and G1-S arrest by suppressing the protein kinase B/c-MYC pathway. These results suggest that CPA4 has an oncogenic effect on lung cancer growth. Taken together, we identified a novel gene in lung cancer that might provide a basis for new therapeutic targets. | Downregulation of CPA4 inhibits non small-cell lung cancer growth by suppressing the AKT/c-MYC pathway.
Fu Y, Su L, Cai M, Yao B, Xiao S, He Q, Xu L, Yang L, Zhao C, Wan T, Shao L, Wang L, Huang X., Free PMC Article | 01/25/2020 |
| Serum CPA4 concentration combined with lymph node involvement may be used as accurate predictors of liver metastasis in colorectal cancer. | Serum carboxypeptidaseA4 levels predict liver metastasis in colorectal carcinoma.
Sun L, Guo C, Burnett J, Yang Z, Ran Y, Sun D., Free PMC Article | 02/24/2018 |
| CPA4 as a negative regulator of adipogenesis that is down-regulated by FGF-1. Expression of CPA4 in subcutaneous adipose tissue correlated negatively with insulin sensitivity. | Fibroblast growth factor-1 (FGF-1) promotes adipogenesis by downregulation of carboxypeptidase A4 (CPA4) - a negative regulator of adipogenesis implicated in the modulation of local and systemic insulin sensitivity.
He J, Chen DL, Samocha-Bonet D, Gillinder KR, Barclay JL, Magor GW, Perkins AC, Greenfield JR, Yang G, Whitehead JP. | 01/13/2018 |
| The crystal structure of the human CPA4 carboxypeptidase in complex with SmCI, a peptide protease inhibitor. | A noncanonical mechanism of carboxypeptidase inhibition revealed by the crystal structure of the Tri-Kunitz SmCI in complex with human CPA4.
Alonso del Rivero M, Reytor ML, Trejo SA, Chávez MA, Avilés FX, Reverter D. | 02/8/2014 |
| NvCL form Nerita versicolor is a tight-binding inhibitor that interacts with the active site of the CPA4 in a substrate-like manner. | Crystal structure of novel metallocarboxypeptidase inhibitor from marine mollusk Nerita versicolor in complex with human carboxypeptidase A4.
Covaleda G, del Rivero MA, Chávez MA, Avilés FX, Reverter D., Free PMC Article | 06/16/2012 |
| CPA4 gene is imprinted, with preferential expression from the maternal allele in many fetal tissues, but not in fetal brain. | The novel imprinted carboxypeptidase A4 gene ( CPA4) in the 7q32 imprinting domain.
Kayashima T, Yamasaki K, Yamada T, Sakai H, Miwa N, Ohta T, Yoshiura K, Matsumoto N, Nakane Y, Kanetake H, Ishino F, Niikawa N, Kishino T. | 10/20/2010 |
| CPA4 functions in neuropeptide processing and regulation in the extracellular environment | Characterization of the substrate specificity of human carboxypeptidase A4 and implications for a role in extracellular peptide processing.
Tanco S, Zhang X, Morano C, Avilés FX, Lorenzo J, Fricker LD., Free PMC Article | 07/5/2010 |
| genetic polymorphism is associated with an increased risk of aggressive prostate cancer among younger patients (< 66 years) | Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer.
Ross PL, Cheng I, Liu X, Cicek MS, Carroll PR, Casey G, Witte JS, Ross PL, Cheng I, Liu X, Cicek MS, Carroll PR, Casey G, Witte JS., Free PMC Articles: PMC2657151, PMC2657151 | 01/21/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | Carboxypeptidase 4 gene variants and early-onset intermediate-to-high risk prostate cancer.
Ross PL, Cheng I, Liu X, Cicek MS, Carroll PR, Casey G, Witte JS, Ross PL, Cheng I, Liu X, Cicek MS, Carroll PR, Casey G, Witte JS., Free PMC Articles: PMC2657151, PMC2657151 | 03/25/2009 |
| The three-dimensional structure of procarboxypeptidase-A4 (hPCPA4) has been solved and shows the features of related metallocarboxypeptidase zymogens, with a preformed alpha/beta/-hydrolase active-enzyme moiety (hCPA4) and an inhibiting pro-domain (PD). | Detailed molecular comparison between the inhibition mode of A/B-type carboxypeptidases in the zymogen state and by the endogenous inhibitor latexin.
García-Castellanos R, Bonet-Figueredo R, Pallarés I, Ventura S, Avilés FX, Vendrell J, Gomis-Rütha FX., Free PMC Article | 01/21/2010 |